Drugs / GRWD0715
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07047703 | Jul 2025 → Apr 2028 expected | spondyloarthropathy | Grey Wolf Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Grey Wolf Therapeutics | Results Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial greywolftherapeutics.com ↗
Single ascending dose (SAD) portion completed in healthy volunteers, with dose-proportional pharmacokinetics (PK), clear evidence of ERAP1 target engagement, and no safety or tolerability concerns observed |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Grey Wolf Therapeutics | Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial greywolftherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRWD0715 | “Participants in Part A will receive a single dose of GRWD0715 on Day 1 only.” NCT07047703 ↗ |
| Action | Inhibit | “As an inhibitor of ERAP1, GRWD0715 aims to prevent the generation of the antigenic self-peptide” NCT07047703 ↗ |
| Route | Oral | “orally administered” NCT07047703 ↗ |
| Target | ERAP1 | “As an inhibitor of ERAP1, GRWD0715 aims to prevent the generation of the antigenic self-peptide” NCT07047703 ↗ |